AIM Therapeutics Inc. is a privately held biotechnology company engaged in the discovery and development of breakthrough medical therapies to improve the lives of people with immune and inflammatory disorders. AIM Therapeutics is focused on the development of novel peptide-based therapeutic candidates for the treatment of asthma, cardiovascular disease, diabetes, spinal cord injury, and other inflammatory conditions and immune disorders with significant unmet medical needs. AIM Therapeutics is pursuing the pre-clinical validation and development of its lead candidates through a virtual business model being managed by BioQuest Innovations Inc.
P: 416.673.8199
Website:
www.aimtherapeutics.com
